Comparison guide

Yohimbine, yohimbe bark or rauwolscine?

All three are alpha-2 blockers from the same family and share the same risks: faster heart rate, higher blood pressure and anxiety. What differs is how well you know the dose. Yohimbine hydrochloride has a studied dose, bark products have unpredictable alkaloid content, and rauwolscine has no human trials at all.

The options, compared

Option	Evidence	Best for	The honest note
Yohimbine	Moderate evidence	Known dose, still risky	Beat placebo for erectile dysfunction at 15–30 mg/day in trials that predate the far more effective PDE5 inhibitors, and its fat-loss evidence is one small trial. In 238 poison-centre cases, 43% had tachycardia and 25% hypertension.	View
Yohimbe Bark Extract	Limited evidence	Avoid — dose unknown	Analyses found yohimbine content ranging from undetectable to many times the label, and whole bark itself has never been tested in a trial. Restricted or banned as a supplement ingredient in several countries.	View
Rauwolscine (Alpha-Yohimbine)	Limited evidence	Avoid — no human data	Sold in fat burners on receptor pharmacology alone; no human trial has tested it for fat loss, and label doses of 0.5–3 mg are set by manufacturers rather than research.	View

Our verdict

None of these is a comfortable recommendation. Yohimbine hydrochloride at least has a known dose and is a prescription medicine in several countries, and for erectile dysfunction PDE5 inhibitors are far more effective. Skip yohimbe bark and rauwolscine, and avoid the whole family if you have anxiety, hypertension, heart or kidney disease, take MAO inhibitors or stimulants, or are pregnant.